Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T? | Zendy

Rhonda L. Bitting | Zendy; Andrew J. Armstrong | Zendy; Daniel J. George | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?

Author(s) -

Rhonda L. Bitting,

Andrew J. Armstrong,

Daniel J. George

Publication year - 2011

Publication title -

clinical medicine insights oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.601

H-Index - 26

ISSN - 1179-5549

DOI - 10.4137/cmo.s5977

Subject(s) - cabazitaxel , abiraterone acetate , prostate cancer , docetaxel , medicine , abiraterone , oncology , prednisone , enzalutamide , food and drug administration , clinical trial , cancer , androgen deprivation therapy , pharmacology , androgen receptor

Most prostate cancer-related deaths occur in patients with castration-resistant prostate cancer (CRPC). Until recently, only therapy with docetaxel and prednisone has been shown to prolong survival in men with metastatic CRPC. With the United States Food and Drug Administration (US FDA) approvals of sipuleucel-T, cabazitaxel, and abiraterone acetate, all based on improvement in overall survival, the landscape for management of men with metastatic CRPC has dramatically changed. In this review we will discuss the pivotal clinical trial data leading to these approvals, with particular focus on the unique indication for sipuleucel-T and the implications for optimal management and sequencing of treatment in this patient population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research